Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma
Latest Information Update: 13 Oct 2023
Price :
$35 *
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- Acronyms PORTEC-3
- 10 Oct 2023 Planned End Date changed from 31 Dec 2027 to 31 Dec 2024.
- 04 Apr 2022 Planned End Date changed from 1 Dec 2027 to 31 Dec 2027
- 01 Feb 2022 Results investigating whether IMRT, compared to 3DCRT, resulted in fewer adverse events and patient-reported symptoms, published in the International Journal of Radiation Oncology, Biology, Physics